|
|
 |
|
Viewing report
|
|
|
|
Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies
GBI Research, Feb 2011, Pages: 209
This report provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline
Early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.
The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.
Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline in Different Therapeutic Segments, December 2010
Source: GBI Research, GBI Research Internal Database, Clinical Trials.gov, Company websites
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
